Craniospinal Irradiation Side Effects in an 8-Year-Old Boy
For an 8-year-old boy receiving craniospinal irradiation (CSI), expect approximately 40% to develop grade 3+ late toxicity, with the most common serious effects being hearing impairment requiring intervention (20.5%) and cognitive impairment prohibiting independent living (18%). 1
Acute Side Effects (During and Immediately After Treatment)
Early Onset (Within 72 Hours)
- Vomiting: 66% of patients
- Headache: 46% of patients 2
Peak Toxicity (Week 3 of Treatment)
When CSI is combined with vincristine chemotherapy:
- Constipation: 56% (vs 0% without vincristine)
- Abdominal pain/cramping: 67% (vs 0% without vincristine) 2
Hematologic Toxicity
- Grade 3-4 leukopenia: 62% with electron technique, 32% with photon technique 3
- Grade 3-4 thrombocytopenia: 21% with electrons, 4% with photons 3
- Younger age (≤6 years) significantly increases hematologic toxicity risk 3
Dermatologic Effects (Week 6)
- Faint erythema: 73% of patients
- Dry desquamation: 40%
- Moist desquamation (confined to skin folds): 33% 2
- Complete alopecia is universal
Gastrointestinal
- Grade 3-4 weight loss: 0% (rare with modern techniques) 3
Important: Despite these acute toxicities, treatment interruptions are rare—only 2-5% of patients require breaks >3 days 3
Late Side Effects (Long-Term, ≥5 Years Post-Treatment)
Overall Late Toxicity Burden
41% of long-term survivors develop grade 3+ toxicity, with this risk particularly elevated in patients receiving CSI doses >23.4 Gy 1
Neurocognitive Effects
- Cognitive impairment prohibiting independent living: 18% 1
- Progressive decline in IQ, particularly with doses >20 Gy to supratentorial brain 4
- Younger age at treatment (<7 years) predicts worse neurocognitive outcomes 5
- Processing speed, working memory, and perceptual reasoning are most affected 5
Hearing Loss
- Hearing impairment requiring intervention: 20.5% 1
Growth and Endocrine Effects
- Hypothyroidism: 40% of long-term survivors 6
- Severe growth impairment: Mean height drops from -0.4 SD (36th percentile) pre-treatment to -2.2 SD (1st percentile) at long-term follow-up (p<0.001) 6
- Disproportionate short stature due to spinal growth plate damage, with greater loss of spinal height than leg length 7
- Growth hormone deficiency common, though GH treatment has limited efficacy after spinal irradiation 7
Musculoskeletal Effects
- Scoliosis: 34% of patients, with median Cobb angle 15° (range 10-35°) 6
- Surgical correction required: 2% 6
Cardiovascular and Cerebrovascular
- Stroke risk: 10-fold increased compared to siblings, particularly with doses >30 Gy 8
- Screening for diabetes and dyslipidemia warranted due to increased cardiovascular risk 8
Secondary Malignancies
- Incidence: 5-10% of long-term survivors 6, 1
- Most common: meningiomas, gliomas, and sarcomas
- Median latency: 7-9 years post-radiation 9
Reproductive Effects
- Precocious puberty: Risk increases with cranial doses ≥18 Gy, particularly in girls <8 years 10
- Ovarian failure/reduced fertility: Significant risk with CSI, though less than with direct gonadal irradiation 10
Pulmonary Effects
- Symptomatic radiation pneumonitis: 0% with modern techniques (helical tomotherapy/IMRT) 11
- Restrictive pulmonary disease: <2% 6
Other Rare but Serious Effects
- Esophageal stricture: <2% 6
- Treatment-related mortality: 5.6% (from radionecrosis, cerebral edema, or secondary malignancy) 1
Critical Factors Affecting Toxicity Risk
Dose-Dependent Effects
- CSI doses >23.4 Gy: Dramatically increased late toxicity risk 1
- Doses >30 Gy: Highest risk for stroke and secondary malignancies 8, 9
Age-Dependent Effects
- Age <6 years at treatment: Higher acute hematologic toxicity 3
- Age <7 years: Worse neurocognitive outcomes 5
- Younger age: More severe growth impairment 7, 6
Technique Considerations
Modern proton therapy (PBSPT) shows promising early results with 92.6% grade ≥3 toxicity-free rate at 2 years 12, suggesting potential for reduced late effects compared to photon-based CSI, though longer follow-up is needed.
Common Pitfalls to Avoid
Do not assume menstruation indicates fertility in female survivors—ovarian reserve is diminished even with regular cycles 10
Do not delay endocrine screening—begin thyroid function monitoring immediately after treatment completion 6
Do not use growth hormone therapy for non-GH-deficient patients with spinal irradiation-induced short stature—it provides minimal benefit and may worsen disproportionate growth 7
Do not overlook cardiovascular screening—begin monitoring for stroke risk factors (hypertension, diabetes, dyslipidemia) during survivorship care 8
Recognize that chemotherapy sequencing matters—pre-CSI chemotherapy increases acute hematologic toxicity by 50-90% compared to post-CSI or no chemotherapy 3